Autor: "Liu, Yunpeng" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
Autorzy:: Ye SL; Liver Cancer Institute, Zhongshan Hospital, Fudan University, 136 Yixueyuan Rd, Shanghai, 200032, China. .
Yang J; Department of Special Treatment, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Bie P; Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.
Zhang S; Department of General Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chen X; Department of Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Liu F; Department of Interventional Radiology, Chinese PLA General Hospital, Beijing, China.
Liu L; Shanghai Cancer Center, Fudan University, Shanghai, China.
Zhou J; Department of Hepatobiliary Surgery, Nanfang Hospital of Southern Medical University, Guangzhou, China.
Dou K; Department of Hepatobiliary Surgery, Xijing Hospital, Xi'an, China.
Hao C; Department of Hepato-Pancreato-Biliary Surgery, Beijing Cancer Hospital, Peking University, Beijing, China.
Shao G; Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, China.
Xia Q; Department of Liver Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Chen Y; Department of Hepatobiliary Surgery, Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Yang J; Department of Nuclear Medicine, Changhai Hospital, Second Military Medical University, Shanghai, China.
Deng X; Department of General Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Liu Y; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.
Yuan Y; Department of Hepatobiliary, Cancer Center, Sun Yat-sen University, Guangzhou, China.
Fu Z; Department of Liver Transplantation, Shanghai Changzheng Hospital, Shanghai, China.
Nakajima K; Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA.
Lv Z; Bayer Healthcare Company Ltd., Beijing, China.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2018 Mar 02; Vol. 18 (1), pp. 247. Date of Electronic Publication: 2018 Mar 02.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents/*therapeutic use
Carcinoma, Hepatocellular/*drug therapy
Drug-Related Side Effects and Adverse Reactions/*etiology
Liver Neoplasms/*drug therapy
Niacinamide/*analogs & derivatives
Phenylurea Compounds/*therapeutic use
Aged ; Antineoplastic Agents/adverse effects ; Carcinoma, Hepatocellular/pathology ; Female ; Follow-Up Studies ; Humans ; Liver Neoplasms/pathology ; Male ; Niacinamide/adverse effects ; Niacinamide/therapeutic use ; Phenylurea Compounds/adverse effects ; Retrospective Studies ; Safety ; Sorafenib ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Liu, Yunpeng"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Język